OPEN END TURBO OHNE STOP-LOSS - FRESENIUS MEDICAL CARE Share Price

Certificat

DE000LS110N6

Real-time Bid/Ask 08:32:05 28/05/2024 BST
3.36 EUR / 3.37 EUR +1.36% Intraday chart for OPEN END TURBO OHNE STOP-LOSS - FRESENIUS MEDICAL CARE
Current month-1.48%
1 month-7.78%
Date Price Change
28/05/24 3.3 -0.60%
27/05/24 3.32 +0.91%
24/05/24 3.29 -1.79%
23/05/24 3.35 +0.90%
22/05/24 3.32 +2.47%

Delayed Quote Börse Stuttgart

Last update May 28, 2024 at 07:10 am

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying FRESENIUS MEDICAL CARE AG
Issuer Lang & Schwarz
WKN LS110N
ISINDE000LS110N6
Date issued 15/08/2016
Strike 70.62
Maturity Unlimited
Parity 10 : 1
Emission price 1.76
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.24
Lowest since issue 0.25
Spread 0.01
Spread %0.30%

Company Profile

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Sector
-
More about the company

Ratings for Fresenius Medical Care AG

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius Medical Care AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
38.77 EUR
Average target price
39.84 EUR
Spread / Average Target
+2.77%
Consensus